PLX Financial Facts

NET LOSS FOR THE PERIOD: -7.29M
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
See Full Income Statement

CAPITAL DEFICIENCY: -15.1M
Trade: 3.99M
See Full Balance Sheet

Protalix Biotherapeutics, Inc. (PLX) Earnings

  |   Expand Research on PLX
Next EPS Date 5/14/21 EPS Growth Rate -270.0%
Average EPS % Beat Rate -16.3% Revenue Growth Rate -49.4%
Average % Move 1-Wk after EPS +2.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/14/21 Q121 N/A-$0.17 N/A N/A$10.95M N/A N/A N/A
3/30/21 Q420 $0.00-$0.08 +$0.08N/A$11.99M N/A Details
10/29/20 Q320 $0.00N/A N/A $10.8M$10.08M N/A Details
8/10/20 Q220 -$0.13-$0.20 +$0.07$10.97M$10.87M N/A Details
6/1/20 Q120 $0.10-$0.30 +$0.40$21.65M$6.6M N/A Details
3/12/20 Q419 $0.02N/A N/A $3.8M$1.8M N/A Details
11/7/19 Q319 -$0.13-$0.03 -$0.10$12.09M$11.6M N/A Details
5/10/17 Q117 -$0.48N/A N/A $2.9M$679K N/A Details